From the Literature: Atopic Dermatitis

Article

Review findings from two recently published studies looking at imaging in atopic dermatitis.

The Self-Administered Eczema Area and Severity Index in Children with Moderate to Severe Atopic Dermatitis: Better Estimation of AD Body Surface Area than SeverityJournal: Pediatric Dermatology (September/October)

Authors: Van Velsen SG, Knol MJ, Haeck IM, et al.

Purpose: The aim of this study was to evaluate the correlation of the Self-Administered Eczema Area and Severity Index (SA-EASI) with two physician-based disease activity scores (objective SCORAD and SASSAD score) and with Thymus and Activation-Regulated Cytokine (TARC), a serum marker for AD, in children with the disease.

Results: The association between the SA-EASI and the objective SCORAD was found to be high, “mainly based on high correlation between the body surface area (BSA) measurements of both scores.” It was concluded that educating parents in the severity scoring of AD “may improve agreement of the SA-EASI and the objective SCORAD, TARC, and SASSAD score, and that additional use of the SA-EASI in routine clinical practice may “facilitate more frequent but still accurate assessment of AD.”

Click here to access this third-party resource.

Eczema Prevalence in the United States: Data from the 2003 National Survey of Children’s HealthJournal: Journal of Investigative Dermatology (September 2010)

Authors: Shaw TE, Currie GP, Koudelka CW, Simpson EL

Purpose: To determine, using data from the 2003 National Survey of Children’s Health, the national prevalence of eczema in the US pediatric population, and to further examine geographic and demographic associations previously reported in other countries.

Results: Researchers found that overall, 10.7% of children were diagnosed with eczema in the past year, with the prevalence ranging from 8.7 to 18.1% between states and districts. Metropolitan living, black race, and educational level were found to be significant factors in predicting higher disease prevalence. “The wide range of prevalence suggests that social or environmental factors may influence disease expression,” they wrote.

Click here to access this third-party resource.

Recent Videos
Discussing Interim Findings on Nemolizumab for Atopic Dermatitis, with Diamant Thaçi, MD
Responding to FDA Approval of Lebrikizumab for Atopic Dermatitis, with Andrew Alexis, MD, MPH
A panel of 3 experts on atopic dermatitis
A panel of 3 experts on atopic dermatitis
Matthew Zirwas, MD: Discussing Upadacitinib, Other JAK Inhibitors for Atopic Dermatitis
Most Exciting New Therapies in Atopic Dermatitis, with Matthew Zirwas, MD
© 2024 MJH Life Sciences

All rights reserved.